BioLife Solutions Inc (OQ:BLFS)
Business Focus: Medical Equipment, Supplies & Distribution
Apr 18, 2024 08:05 am ET
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business
BOTHELL, Wash., April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").
Feb 20, 2024 07:03 am ET
BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024
BOTHELL, Wash., Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update.
Jan 08, 2024 07:15 am ET
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million
Nov 09, 2023 03:04 pm ET
BioLife Solutions Reports Third Quarter 2023 Financial Results
Conference call begins at 4:30 p.m. Eastern time today
Nov 02, 2023 04:03 pm ET
BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023
BOTHELL, Wash., Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Oct 19, 2023 05:04 pm ET
BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023
Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience
Jul 27, 2023 04:03 pm ET
BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023
BOTHELL, Wash., July 27, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter financial results will be released after market close on Tuesday, August 8, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Jul 26, 2023 01:30 pm ET
Northland Capital Markets Institutional Investor Conference
MINNEAPOLIS, MN / ACCESSWIRE / July 26, 2023 / We are pleased to be hosting the Northland Capital Markets Institutional Investor Conference 2023 on Tuesday September 19, 2023, at the Minneapolis Marriott City Center, Downtown Minneapolis. We have over 90 companies to participating. The format will be 10 one-on-one meetings (or small group) scheduled in 35 minute increments.
Jun 06, 2023 08:03 am ET
BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer
Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order
May 10, 2023 04:03 pm ET
BioLife Solutions Reports First Quarter 2023 Financial Results
Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%
May 02, 2023 04:03 pm ET
BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023
BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Mar 16, 2023 04:03 pm ET
BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results
Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and services supplier
Mar 09, 2023 03:03 pm ET
BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023
BOTHELL, Wash., March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2022 financial results will be released after market close on Thursday, March 16, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Jan 26, 2023 08:00 am ET
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE:...
Jan 17, 2023 07:04 am ET
BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences
BOTHELL, Wash., Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and upcoming investor conferences where management will be presenting and meeting with current and prospective investors.
Jan 10, 2023 07:05 am ET
BioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work For
Fourth Time Company Recognized in the Last Nine Years
Jan 09, 2023 07:05 am ET
BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance
Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37%
Dec 19, 2022 07:03 am ET
BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023
Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue
Nov 21, 2022 07:05 am ET
BioLife Solutions Expands Intellectual Property Estate
7 New Granted Patents; 43 Submitted Patent Applications
Nov 17, 2022 07:05 am ET
BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report
Only 60 Companies Selected – Based on 2,000 Respondents
Nov 09, 2022 03:05 pm ET
BioLife Solutions Reports Third Quarter 2022 Financial Results
Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier
Nov 02, 2022 04:05 pm ET
BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022
BOTHELL, Wash., Nov. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2022 financial results will be released after market close on Wednesday, November 9th. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Oct 11, 2022 06:00 am ET
CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market
CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform
Oct 11, 2022 06:00 am ET
CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market
CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform
Oct 03, 2022 08:03 am ET
BioLife Solutions Announces COO to Retire and Join Board of Directors
Roderick de Greef retirement planned for January 2023 with appointment to BioLife Board of Directors
Aug 25, 2022 08:03 am ET
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process
Aug 09, 2022 04:07 pm ET
BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance
Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46%
Aug 02, 2022 04:05 pm ET
BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022
BOTHELL, Wash., Aug. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9th. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Jun 09, 2022 08:05 am ET
BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services
The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level
May 09, 2022 04:03 pm ET
BioLife Solutions Reports First Quarter 2022 Financial Results
Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53%
May 09, 2022 08:05 am ET
BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services
BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that it has executed a co-marketing agreement with Coriell Institute of Medical Research. Under the terms of the agreement, BioLife, under its SciSafe® brand, will promote Coriell's biospecimen processing services and Coriell will promote BioLife's biologic storage services to the scientific research and biopharma markets. The parties will share revenue
May 02, 2022 07:28 pm ET
BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022
BOTHELL, Wash., May 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2022 financial results will be released after market close on Monday, May 9th. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Apr 07, 2022 04:45 pm ET
BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP
BOTHELL, Wash., April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced that its Audit Committee (the "Committee") approved the engagement of Grant Thornton LLP ("Grant Thornton") as the Company's new independent registered public accounting firm, effective April 6, 2022. The Company dismissed its prior registered independent public accounting firm following its request for pr
Mar 18, 2022 05:43 pm ET
BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing
BOTHELL, Wash., March 18, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and biopharma markets, announced today that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 (the "Form 10-K"). The Notice advised the Company that it was not in compliance with N
Mar 17, 2022 08:05 am ET
BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K
BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the "Form 10-K").
Mar 15, 2022 08:05 am ET
BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market
BOTHELL, Wash., March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided additional details on its growth expectations for the Company's SciSafe® biostorage services platform.
Mar 01, 2022 07:05 am ET
BioLife Solutions to Attend and Present at Upcoming Investor Conferences
BOTHELL, Wash., March 1, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced Mike Rice, Chairman and CEO, Rod de Greef, President and COO, and Troy Wichterman, CFO, are scheduled to present at both the Cowen and KeyBanc Investor Conferences in March 2022.
Feb 28, 2022 03:03 pm ET
BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results
BOTHELL, Wash., Feb. 28, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced unaudited financial results for the three and 12 months ended December 31, 2021 and introduced 2022 revenue guidance.
Feb 21, 2022 07:03 am ET
BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022
BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2021 financial results will be released after market close on Monday, February 28th. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Jan 10, 2022 07:00 am ET
BioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020
BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.
Jan 04, 2022 07:06 am ET
BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing
BOTHELL, Wash., Jan. 4, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an extended collaboration with Seattle Children's Therapeutics, a venture at Seattle Children's, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children. The collaboration will focus on establishing best practices in biopreservation and closed-system manufacturing with the introduction and integ
Dec 16, 2021 07:03 am ET
UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines
BOTHELL, Wash., Dec. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced a partnership with UNICEF to extend thermal stability of temperature-sensitive COVID-19 vaccines in developing communities in Africa, the Middle East and South America where limited power infrastructure and extreme environmental conditions make it difficult for most ULT freezers to remain operational. As part of this program, UNICEF has approved Stirlin
Nov 17, 2021 12:08 pm ET
BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™
BOTHELL, Wash., Nov. 17, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced it has ranked 353 in the 27th annual Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. BioLife Solutions annual revenue grew 336% from 2017 to 2020, driven by organic growth and several acquisitions that were completed to broaden
Nov 15, 2021 07:05 am ET
BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies
BOTHELL, Wash., Nov. 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, today announced that it was named to Inc. Magazine's inaugural list of the 250 best-led companies in the United States.
Nov 11, 2021 03:05 pm ET
BioLife Solutions Announces Third Quarter 2021 Financial Results
BOTHELL, Wash., Nov. 11, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three and nine months ended September 30, 2021.
Nov 04, 2021 04:05 pm ET
BioLife Solutions Announces Executive Management Changes
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.
Nov 04, 2021 08:03 am ET
BioLife Solutions to Report Third Quarter 2021 Financial Results and Provide Business Update on November 11, 2021
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2021 financial results will be released after market close on Thursday, November 11th. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
Oct 26, 2021 08:05 am ET
Biolife Solutions Supports Biostorage Best Practices Through SciSafe's "Centers of Excellence" With New World-Class Facility in Amsterdam
BOTHELL, Wash., Oct. 26, 2021 /PRNewswire/ -- Biolife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for cell and gene therapies ("CGT"), and its biological material storage brand SciSafe, a multi-facility provider of storage services to the CGT and broader biopharma market, today announced the opening of a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, adjacent to the Schiphol Airport.
Oct 04, 2021 08:00 am ET
BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer
BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze media, evo cold chain management platform and SciSafe storage services with Stirling UltraCold freezers are all being utilized by this top 10 largest global pharmaceutical company to support the anticipated regulatory approval and commercial launch of a new
Sep 20, 2021 08:00 am ET
BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors
BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions. Mr. Goswami replaces Andrew Hinson, who has retired from the board.
Sep 15, 2021 08:00 am ET
BioLife Solutions Announces CFO Retirement
BOTHELL, Wash., Sept. 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Roderick de Greef, Chief Financial Officer, plans to retire on December 31, 2021 after a distinguished career with the Company. The Company has retained executive search firm Strawn Arnold to identify candidates to succeed Mr. de Greef. Mr. de Greef will consult with the Company through March 31, 2022, to ensu
Sep 01, 2021 05:36 pm ET
BioLife Solutions Files Form S-3 Registration Statement to Register Shares from Completed Acquisitions
BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, announces that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission ("SEC") to register approximately 10.7 million shares of restricted common stock held by stockholders of previously acquired companies Global Cooling, Inc. (operating as Stirling Ultracold), SciSafe Holdings, Inc. and Sexton
Sep 01, 2021 09:08 am ET
BioLife Solutions Closes Acquisition of Sexton Biotechnologies
BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies.
Aug 25, 2021 11:14 am ET
BioLife Solutions Joins S&P SmallCap 600 Index
BOTHELL, Wash., Aug. 25, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that its common stock will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021.
Aug 24, 2021 06:03 pm ET
Bio-Techne Set to Join S&P 500; Saia, Mimecast & Option Care Health to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening of trading on Monday, August 30:
Aug 12, 2021 04:05 pm ET
BioLife Solutions Announces Second Quarter 2021 Financial Results
BOTHELL, Wash., Aug. 12, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three and six months ended June 30, 2021.
Aug 09, 2021 08:06 am ET
Sexton Biotechnologies to be Acquired by Biolife Solutions
INDIANAPOLIS, Aug. 9, 2021 /PRNewswire/ -- Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (CGT) industry, today announced that it has entered into a definitive agreement whereby BioLife Solutions (NASDAQ: BLFS) will acquire all outstanding shares of the company in a deal worth a total value of $30 million. During the past two years, Sexton has worked to provide end-to-end solutions for emerging cell and gene therapy manufacturers. The merger with BioLife will expand Sexton's ability to meet market demands for their innovative tools such as C
Aug 09, 2021 08:00 am ET
BioLife Solutions to Acquire Sexton Biotechnologies to Expand Cell and Gene Therapy Tools Portfolio
BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton Biotechnologies, Inc., that it does not currently own, for $24.0 million, in consideration for 506,382 newly issued shares of BioLife common stock. Taking into consideration liquidation preferences, Bio
Aug 05, 2021 08:00 am ET
BioLife Solutions to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
BOTHELL, Wash., Aug. 5, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that the Company's second quarter 2021 financial results will be released after market close on Thursday, August 12, 2021, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial resul
Jul 14, 2021 08:00 am ET
BioLife Solutions Announces Changes to Board of Directors
BOTHELL, Wash., July 14, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced changes to its board of directors.
Jun 15, 2021 08:00 am ET
BioLife Solutions Adopts New Brand Identity
BOTHELL, Wash., June 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the launch of its new corporate brand identity, redesigned logo, and website. The new brand identity was created to better reflect BioLife's expanded portfolio of bioproduction tools and services.
Feb 16, 2021 07:00 am ET
BioLife Solutions Promotes Marcus Schulz to Chief Revenue Officer
BOTHELL, Wash., Feb. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Chief Revenue Officer. He was previously Vice President of Global Sales.
Dec 01, 2020 08:00 am ET
iVexSol Announces Series A Funding
iVexSol, a rapidly growing lentiviral vector (LVV) manufacturing company, today announced the closure of a $13.0M Series A funding round. A total of $15.2M has been raised to date from current investors Casdin Capital, LLC , and BioLife Solutions...
Dec 01, 2020 07:00 am ET
BioLife Solutions & Casdin Capital Innovation Accelerator Announce New Investments in Cell & Gene Therapy Bioproduction Tools
BOTHELL, Wash., Dec. 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced two new co-investments with innovation accelerator partner Casdin Capital. The first is a re-investment in iVexSol, a vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process. BioLife Solutions invested $1 million and Casdin invested $4 million in a $15.2 million Series A finan
Nov 19, 2020 07:00 am ET
BioLife Solutions Ranked 403rd Fastest Growing Company in North America on Deloitte's 2020 Technology Fast 500™
BOTHELL, Wash., Nov. 19, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced it was ranked number 403 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. BioLife Solutions' revenue grew 233% from 2016 through 2019.
Nov 05, 2020 03:05 pm ET
BioLife Solutions Announces Third Quarter 2020 Financial Results
BOTHELL, Wash., Nov. 5, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results for the three and nine months ended September 30, 2020.
Oct 29, 2020 04:05 pm ET
BioLife Solutions to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020
BOTHELL, Wash., Oct. 29, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that the Company's third quarter 2020 financial results will be released after market close on Thursday, November 5th, 2020, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business upda
Oct 14, 2020 08:00 am ET
BioLife Solutions SciSafe Division Secures $2.7 Million Cold Chain and Storage Contract for COVID-19 Vaccines
BOTHELL, Wash., Oct. 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools and services for cell and gene therapies, today announced its recently acquired SciSafe division has been awarded a two year contract from a large pharmaceutical company for cold chain management and storage of COVID-19 vaccines. The contract value is approximately $2.7 million.
Aug 06, 2020 04:05 pm ET
BioLife Solutions Announces Second Quarter 2020 Financial Results
BOTHELL, Wash., Aug. 6, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three and six months ended June 30, 2020.
Jul 30, 2020 05:45 pm ET
BioLife Solutions to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020
BOTHELL, Wash., July 30, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced that the Company's second quarter 2020 financial results will be released after market close on Thursday, August 6th, 2020, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Jul 15, 2020 08:00 am ET
BioLife Solutions evo® Cold Chain Management Platform Now Supporting Over 100 Early Stage Cell & Gene Therapy Clinical Trials
BOTHELL, Wash., July 15, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today provided an update on adoption of its evo cold chain management platform solution by cell and gene therapy companies.
Jul 07, 2020 12:45 pm ET
BioLife Solutions Announces Closing of $86 Million Public Offering of Common Stock
BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price of $14.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters' option to purchase up to an additional 776,250 shares of its common stock. The gross proceeds from the offering to BioLife, before deducting u
Jul 02, 2020 07:40 am ET
BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock
BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75 million.
Jul 01, 2020 04:02 pm ET
BioLife Solutions Announces $9.6 Million to $9.8 Million in Preliminary Revenue for Q2 2020
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced estimated preliminary revenue for the second quarter of 2020 of $9.6 million to $9.8 million, representing 43% to 46% growth over the same quarter in 2019.
Jul 01, 2020 04:01 pm ET
BioLife Solutions Announces Proposed Public Offering of Common Stock
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, BioLife expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares to be issued and sold in the public offering on the same terms and conditions. The offering is subject to market and other conditi
May 18, 2020 04:15 pm ET
BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales
BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales. He is replacing Jim Mathers, Chief Revenue Officer, who is retiring on June 30, 2020.
May 14, 2020 04:05 pm ET
BioLife Solutions Announces First Quarter 2020 Financial Results
BOTHELL, Wash., May 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three months ended March 31, 2020.
May 11, 2020 08:00 am ET
BioLife Solutions to Report First Quarter 2020 Financial Results and Provide Business Update on May 14th, 2020
BOTHELL, Wash., May 11, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that the Company's first quarter 2020 financial results will be released after market close on Thursday, May 14th, 2020, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
May 01, 2020 08:00 am ET
BioLife Solutions Announces Preliminary First Quarter 2020 Revenue
BOTHELL, Wash., May 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced preliminary revenue for the first quarter of 2020.
Nov 12, 2019 03:03 pm ET
BioLife Solutions Acquires Custom Biogenic Systems
BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition of substantially all of the assets of Custom Biogenic Systems, Inc. ("CBS"). CBS, a privately held company with operations located near Detroit, is a global leader in the design and manufacture of state-of-the-art liquid nitrogen laboratory freezers and cryogenic equipment. CBS also offers a related cloud-based monitoring system that
Nov 12, 2019 03:01 pm ET
BioLife Solutions Announces Third Quarter 2019 Financial Results
BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational highlights for the three and nine months ended September 30, 2019. The Company also revised 2019 financial guidance to reflect the acquisition of Custom Biogenic Systems, Inc. ("CBS") announced earlier today and introduced preliminary 2020 revenue guidance.
Nov 07, 2019 07:00 am ET
BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte's 2019 Technology Fast 500™
BOTHELL, Wash., Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list.
Oct 31, 2019 08:23 pm ET
BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
BOTHELL, Wash., Oct. 31, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial results will be released after market close on Tuesday, November 12, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Oct 14, 2019 08:00 am ET
BioLife Solutions Awarded Three New Patents for Cryopreservation, Thawing and Cold Chain Transport Technologies
BOTHELL, Wash., Oct. 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for inventions related to cryopreservation, thawing and cold chain transport technologies. The new patents awarded to BioLife include:
Sep 24, 2019 08:00 am ET
BioLife Solutions Announces Cell and Gene Therapy Bioproduction Innovation Accelerator
BOTHELL, Wash., Sept. 24, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with Casdin Capital, targeting early stage companies that are developing novel cell and gene therapy bioproduction tools.
Sep 24, 2019 08:00 am ET
iVexSol Announces $2M in Seed Funding
iVexSol, a newly formed viral vector manufacturing company, today announced $2.0 million in new convertible debt funding led by Casdin Capital, LLC and BioLife Solutions (NASDAQ:BLFS). The company is founded on a next generation manufacturing...
Sep 16, 2019 08:00 am ET
BioLife Solutions Announces New evo® Cold Chain Customers
BOTHELL, Wash., Sept. 16, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have adopted the evo cold chain management system in clinical trials targeting cancer and other leading causes of death. The evo system was designed by SAVSU Technologies, which was acquired by BioLife in August 2019.
Sep 03, 2019 08:00 am ET
Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
BOTHELL, Wash., Sept. 3, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, has adopted BioLife's CryoStor cell freeze media and evo cold chain system for use in current and upcoming clinical trials.
Aug 28, 2019 08:00 am ET
BioLife Solutions Strengthens Sales Team with Key Leadership Additions
BOTHELL, Wash., Aug. 28, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key sales executives who will assist in building and leading the worldwide sales organization. Both executives report to Jim Mathers, Vice President of Global Sales.
Aug 12, 2019 08:00 am ET
BioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences
BOTHELL, Wash., Aug. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that representatives of the Company will be attending, exhibiting, and/or presenting at the following upcoming scientific and investor conferences:
Aug 08, 2019 04:05 pm ET
BioLife Solutions Announces Second Quarter 2019 Financial Results
BOTHELL, Wash., Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational highlights for the three and six months ended June 30, 2019.
Aug 08, 2019 08:05 am ET
BioLife Solutions Completes Acquisition of SAVSU Technologies
BOTHELL, Wash., Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies.
Jul 31, 2019 08:00 am ET
BioLife Solutions to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
BOTHELL, Wash., July 31, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's second quarter 2019 financial results will be released after market close on Thursday, August 8, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Jul 30, 2019 08:00 am ET
SAVSU Technologies Expands IP Portfolio with Risk Mitigation Technologies for Shipping Cell and Gene Therapies
BOTHELL, Wash., July 30, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies, and soon to be acquired by BioLife, has completed a significant expansion of its intellectual property portfolio related to protecting high value cell and gene therapies during storage and distribution.
Jul 23, 2019 08:00 am ET
SAVSU Technologies Partners with United Cargo® to Improve Cold Chain Management and Delivery of Cell and Gene Therapies
BOTHELL, Wash., July 23, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies, has partnered with United Cargo to offer timely, efficient, same-day airport-to-airport service of vital medical shipments when time is of the utmost importance.
Jul 08, 2019 08:00 am ET
BioLife Solutions to Acquire SAVSU Technologies
BOTHELL, Wash., July 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies, today announced that it has exercised its option to acquire the remaining 56% of the outstanding shares of privately held SAVSU Technologies that BioLife currently does not own in exchange for 1.1 million shares of BioLife common stock. The acquisition will be pursuant to a share purchase agreement and is expected to close within 45 days.
May 09, 2019 04:05 pm ET
BioLife Solutions Announces First Quarter 2019 Financial Results
BOTHELL, Wash., May 9, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies, today reported financial results and operational highlights for the three months ended March 31, 2019.
May 02, 2019 08:00 am ET
BioLife Solutions to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
BOTHELL, Wash., May 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's first quarter 2019 financial results will be released after market close on Thursday, May 9, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Apr 08, 2019 07:55 am ET
Market Trends Toward New Normal in Continental Resources, Merit Medical, Global Medical REIT, Cardinal Health, BioLife Solutions, and ChannelAdvisor — Emerging Consolidated Expectations, Analyst Ratin
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Continental Resources, Inc. (NYSE:CLR), Merit Medical Systems, Inc....
Apr 02, 2019 08:00 am ET
BioLife Solutions Completes Acquisition of Astero Bio
BOTHELL, Wash., April 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has closed the previously announced transaction for the acquisition of Astero Bio Corporation ("Astero"), an innovator in the design, development and commercialization of novel automated thawing devices for cell and gene therapies, for an upfront cash payment of $8 million.
Mar 14, 2019 04:05 pm ET
BioLife Solutions Announces Fourth Quarter and Full Year 2018 Financial Results
BOTHELL, Wash., March 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operational highlights for the fourth quarter and full year ended December 31, 2018.
Mar 14, 2019 08:00 am ET
BioLife Solutions Expands Cell and Gene Therapy Tools Portfolio with Acquisition of Astero Bio
BOTHELL, Wash., March 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has entered into an agreement to acquire Astero Bio Corporation ("Astero"), a privately-held innovator in the design, development and commercialization of novel automated thawing devices, for an upfront cash payment of $8.0 million.
Mar 04, 2019 07:00 am ET
BioLife Solutions to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on March 14, 2019
BOTHELL, Wash., March 4, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's fourth quarter and full year 2018 financial results will be released after market close on Thursday, March 14, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general bu
Feb 19, 2019 07:00 am ET
BioLife Solutions to Attend and Present at Upcoming Investor and Scientific Conferences
BOTHELL, Wash., Feb. 19, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that management and scientific personnel will be attending and presenting at the following upcoming events:
Jan 22, 2019 08:58 am ET
SAVSU Technologies Launches Two New evo® Smart Shipper Models to Improve Apheresis Collection Shipments and Cryopreserved Cell and Gene Therapies
ALBUQUERQUE, N.M., Jan. 22, 2019 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart precision shipping containers and cloud-based cold chain management solutions, today announced a major product line expansion and extension, with the launch of two new shippers in its industry-best evo cold chain management system.
Jan 22, 2019 07:00 am ET
New Policies to Advance Development of Cell and Gene Therapies Announced by FDA
BOTHELL, Wash., Jan. 22, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new policies to advance the development of safe and effective cell and gene therapies as set forth in a statement issued by the U.S. Food and Drug Administration (FDA) on January 15, 2019.
Dec 11, 2018 08:00 am ET
Consolidated Research: 2018 Summary Expectations for Enbridge Energy Partners, Sprouts Farmers Market, BioLife Solutions, PagSeguro Digital, NutriSystem, and Employers — Fundamental Analysis, Key Perf
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Enbridge Energy Partners, L.P. (NYSE:EEP), Sprouts Farmers Market, Inc....
Nov 27, 2018 07:00 am ET
BioLife Solutions Completes Redemption of Series A Preferred Stock
BOTHELL, Wash., Nov. 27, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, ("BioLife" or the "Company"), today announced it will redeem the remaining 3,187 shares of Series A Redeemable Preferred stock outstanding for $3,187,000. There are no Series A shares remaining for future redemption.
Nov 13, 2018 07:00 am ET
BioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences
BOTHELL, Wash., Nov. 13, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that management and scientific personnel will be attending and presenting at the following upcoming events:
Nov 08, 2018 03:05 pm ET
BioLife Solutions Announces Third Quarter 2018 Financial Results
BOTHELL, Wash., Nov. 8, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today reported financial results and operational highlights for the three and nine months ended September 30, 2018.
Nov 05, 2018 07:00 am ET
SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis
ALBUQUERQUE, N.M., Nov. 5, 2018 /PRNewswire/ -- SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform ("SAVSU"), today announced that it is supplying its evo Smart Shipper and evo.is to AveXis, a gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases.
Nov 01, 2018 08:00 am ET
BioLife Solutions to Report Third Quarter 2018 Financial Results and Provide Business Update on November 8, 2018
BOTHELL, Wash., Nov. 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Oct 18, 2018 07:40 am ET
Market Trends Toward New Normal in Rambus, GMS, Advanced Energy Industries, AZZ, BioLife Solutions, and Spartan Motors — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rambus, Inc. (NASDAQ:RMBS), GMS Inc. (NYSE:GMS), Advanced Energy...
Oct 01, 2018 08:00 am ET
BioLife Solutions Reports Record Third Quarter 2018 Preliminary Revenue of $5.3 Million, up 79% Year-over-Year
BOTHELL, Wash., Oct. 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported preliminary revenue for the three months ended September 30, 2018 and provided updated revenue guidance for the full year of 2018.
Sep 05, 2018 08:00 am ET
BioLife Solutions Increases Ownership in SAVSU Technologies to 44% with $5 Million Investment
BOTHELL, Wash., Sept. 5, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that it has increased its ownership of SAVSU Technologies from approximately 31% to 44% with a $5 million investment. SAVSU will use the investment to scale up its operations and inventory to support increased demand for its evo® Dry Vapor Shippers and other precision temperature controlled shipping containers for cell and gene therapies.
Aug 24, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Seres Therapeutics, Barnes & Noble, Carbo Ceramics, BioLife Solutions, CareDx, and Syntel — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Seres Therapeutics, Inc. (NASDAQ:MCRB), Barnes Noble, Inc. (NYSE:BKS),...
Aug 22, 2018 08:00 am ET
BioLife Solutions to Ring NASDAQ Closing Bell on August 29, 2018
BOTHELL, Wash., Aug. 22, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that CEO Mike Rice, accompanied by the senior management team and board of directors, will ring the Nasdaq Stock Market Closing Bell on Wednesday, August 29th. The ceremony, which will take place between 3:45 p.m. and 4:15 p.m. Eastern Time, will stream live online at https://new.livestream.com/nasdaq/live.
Aug 09, 2018 08:15 am ET
BioLife Solutions Announces Second Quarter 2018 Financial Results
BOTHELL, Wash., Aug. 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operational highlights for the three and six months ended June 30, 2018.
Aug 09, 2018 08:05 am ET
Casdin Capital Invests $20 Million in BioLife Solutions to Support Strategic Growth Opportunities
BOTHELL, Wash., Aug. 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that Casdin Capital LLC, ("Casdin") a New York-based, life science-focused investment firm and current stockholder of BioLife, has agreed to invest $20 million in BioLife to support the Company's growth strategy of acquiring synergistic cell and gene therapy manufacturing tools and services or technologies.
Aug 06, 2018 08:00 am ET
BioLife Solutions to Present and Exhibit at Fall Investor and Cell & Gene Therapy Conferences
BOTHELL, Wash., Aug. 6, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that representatives will be presenting and exhibiting at the following healthcare conferences:
Aug 02, 2018 08:00 am ET
BioLife Solutions to Report Second Quarter 2018 Financial Results and Provide Business Update on August 9, 2018
BOTHELL, Wash., Aug. 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the Company's second quarter 2018 financial results will be released before market open on Thursday, August 9, 2018, and that the Company will host a conference call and live webcast at 10:00 a.m. ET (7:00 a.m. PT) that morning. Management will provide an overview of the Company's financial results and a general business update.
Jul 31, 2018 08:03 am ET
SAVSU Technologies Awarded New Patent for Cold Chain Technologies Used in Cell and Gene Therapies
ALBUQUERQUE, N.M., July 31, 2018 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the USPTO has issued a notice of allowance of patent number 10,018,614 B2, titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials". The inventors are Bruce McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions (NASDAQ:BLFS).
Jul 09, 2018 08:00 am ET
Sandler Capital Funds to Increase Shareholding in BioLife Solutions
BOTHELL, Wash., July 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that two funds managed by Sandler Capital Management, ("Sandler Capital") a New York-based, sophisticated investor, active in the life science tools and services space, has entered into an agreement to purchase 500,000 BioLife Solutions common shares in a private transaction with the Company's two largest shareholders, who have been a primary source of investment
Jul 02, 2018 08:00 am ET
BioLife Solutions Reports Second Quarter 2018 Preliminary Revenue of $5.2 Million, up 103% Year-over-Year and 36% Sequentially
BOTHELL, Wash., July 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported preliminary revenue for the three months ended June 30, 2018 and increased its revenue guidance for 2018.
Jun 20, 2018 07:55 am ET
Consolidated Research: 2018 Summary Expectations for Xenia Hotels & Resorts, GMS, Schnitzer Steel Industries, BioLife Solutions, Pinnacle Foods, and Ennis — Fundamental Analysis, Key Performance Indic
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Xenia Hotels Resorts, Inc. (NYSE:XHR), GMS Inc. (NYSE:GMS), Schnitzer...
Jun 11, 2018 12:49 pm ET
BioLife Solutions to Join Russell Microcap® Index
BOTHELL, Wash., June 11, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced that it is set to join the Russell Microcap® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25th, according to a preliminary list of additions posted June 8th.
May 29, 2018 08:00 am ET
BioLife Solutions to Present at the 2018 BIO International Convention
BOTHELL, Wash., May 29, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced Michael Rice, CEO, and Roderick de Greef, CFO, will be attending and presenting at the 2018 BIO International Convention, June 4 – 7, 2018, at the Boston Convention and Exhibition Center.
May 17, 2018 08:00 am ET
BioLife Solutions Announces Partial Redemption of Series A Preferred Stock
BOTHELL, Wash., May 17, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, ("BioLife" or the "Company"), today announced it has redeemed 25% of the 4,250 shares of Series A Redeemable Preferred stock outstanding for $1,063,000. There are 3,187 Series A shares remaining for future redemption, with a value of $1,000 per share.
May 16, 2018 08:00 am ET
BioLife Solutions Makes Investment in SAVSU Technologies to Support Growth and Capture Additional Regenerative Medicine Cold Chain Opportunities
BOTHELL, Wash., May 16, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, ("BioLife" or the "Company"), today announced a $1 million equity investment in SAVSU Technologies, Inc. ("SAVSU"), a designer and manufacturer of innovative, high-performance cloud-connected storage and transport containers optimized for the cell and gene therapy supply chain. BioLife Solutions now owns 31% of SAVSU Technologies, up from 26% previously, after all historical capital contributions are accoun
May 10, 2018 04:05 pm ET
BioLife Solutions Announces First Quarter 2018 Financial Results
BOTHELL, Wash., May 10, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operational highlights for the first quarter of 2018.
May 03, 2018 08:00 am ET
BioLife Solutions to Report First Quarter 2018 Financial Results and Provide Business Update on May 10, 2018
BOTHELL, Wash., May 3, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Apr 30, 2018 08:00 am ET
BioLife Solutions Receives $2.6 Million from Exercise of Warrants
BOTHELL, Wash., April 30, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced the receipt of $2.6 million in proceeds from the exercise of 540,896 common stock purchase warrants since April 2, 2018. Each warrant was exercised to purchase one share of common stock for $4.75 per share. The warrants were issued as part of a financing completed in March 2014, and were exercised by several unaffiliated holders. No induceme
Apr 26, 2018 08:15 am ET
Detailed Research: Economic Perspectives on Natural Health Trends, BioLife Solutions, The Chefs' Warehouse, Vocera Communications, GMS, and Enable Midstream Partners, LP — What Drives Growth in Today'
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural Health Trends Corp. (NASDAQ:NHTC), BioLife...
Apr 09, 2018 08:00 am ET
Casdin Capital to Become Shareholder in BioLife Solutions
BOTHELL, Wash., April 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that Casdin Capital LLC, ("Casdin") a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company's second largest shareholder, who has been a primary source of investment capital for the Company since its inception.
Apr 02, 2018 08:00 am ET
BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially
BOTHELL, Wash., April 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced preliminary revenue for the three months ended March 31, 2018.
Mar 26, 2018 08:00 am ET
BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies
BOTHELL, Wash. and ALBUQUERQUE, N.M., March 26, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the USPTO has issued a notice of allowance for a second patent application titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature S
Mar 13, 2018 08:00 am ET
BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research
BOTHELL, Wash., March 13, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation.
Mar 08, 2018 03:05 pm ET
BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results
BOTHELL, Wash., March 8, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operational highlights for the three and 12 months ended December 31, 2017.
Mar 01, 2018 03:15 pm ET
BioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018
BOTHELL, Wash., March 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update
Feb 28, 2018 08:30 am ET
New Research Coverage Highlights PROS, BioLife Solutions, Home BancShares, Revance Therapeutics, HomeStreet, and Ennis — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PROS Holdings, Inc. (NYSE:PRO), BioLife Solutions,...
Feb 13, 2018 07:00 am ET
BioLife Solutions Executes OEM Agreement with MilliporeSigma
BOTHELL, Wash., Feb. 13, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that it has executed an OEM agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media under private label to MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany.
Jan 23, 2018 08:52 am ET
BioLife Solutions Announces SAVSU Alliance with World Courier
BOTHELL, Wash., Jan. 23, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that its joint venture partner SAVSU Technologies ("SAVSU") will supply SAVSU smart precision shipping containers throughout the World Courier network. SAVSU designs and manufactures innovative high-performance cloud-connected passive storage and transport containers optimized for the cell and gene therapy supply chain. World Courier is the global leader in speci
Jan 18, 2018 05:30 am ET
SAVSU Technologies and BioLife Solutions Increase evo® Intellectual Property Estate with Notice of Allowance of New Patent for Cold Chain Technologies
BOTHELL, Wash. and ALBUQUERQUE, N.M., Jan. 18, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the USPTO has issued a notice of allowance of a patent application titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive B
Jan 16, 2018 05:30 am ET
BioLife Solutions to Attend and Present at Upcoming Investor & Scientific Conferences
BOTHELL, Wash., Jan. 16, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that CEO Mike Rice and CFO Roderick de Greef will be attending and presenting at the following investor conferences:
Jan 04, 2018 05:30 am ET
BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million
BOTHELL, Wash., Jan. 4, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018.
Jan 02, 2018 07:45 am ET
Detailed Research: Economic Perspectives on Advanced Energy Industries, News Corporation, Ethan Allen Interiors, Inogen, PROS, and BioLife Solutions — What Drives Growth in Today's Competitive Landsca
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advanced Energy Industries, Inc. (NASDAQ:AEIS), News...
Dec 13, 2017 05:30 am ET
BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics
BOTHELL, Wash., Dec. 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. ("Iovance") (NASDAQ: IOVA). Iovance is currently conducting several clinical trials for tumor infiltrating lymphocyte (TIL) therapies targeting multiple solid tumor types including metastatic melanoma, rec
Nov 29, 2017 05:30 am ET
BioLife Solutions Executes Additional Long-Term Supply Agreement with Leading T Cell Therapy Customer
BOTHELL, Wash., Nov. 29, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that it has executed a new confidential agreement to supply its proprietary CryoStor® cell freeze media to a leading T cell therapy customer. To date, BioLife has executed long-term supply agreements with Adaptimmune, Bellicum Pharmaceuticals, Celyad, Kite Pharma, TissueGene, TxCell and two unnamed customers.
Nov 09, 2017 04:05 pm ET
BioLife Solutions Announces Third Quarter 2017 Financial Results
BOTHELL, Wash., Nov. 9, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operational highlights for the three and nine months ended September 30, 2017.
Nov 02, 2017 07:30 am ET
BioLife Solutions to Report Third Quarter 2017 Financial Results and Provide Business Update on November 9, 2017
BOTHELL, Wash., Nov. 2, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's third quarter 2017 financial results will be released after market close on Thursday, November 9, 2017, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Oct 31, 2017 07:30 am ET
BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies
BOTHELL, Wash. and ALBUQUERQUE, N.M., Oct. 31, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and SAVSU, the leading developer of smart, precision shipping containers and cloud-based cold chain management SaaS solutions, today announced both companies are providing their respective enhanced cold chain technologies for use in 8 active and pending clinical trials conducted by the Diabetes Center and Department of Surgery at the Unive
Oct 30, 2017 07:30 am ET
BioLife Solutions Receives $1.9 Million from Exercise of Warrants
BOTHELL, Wash., Oct. 30, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced the receipt of $1.9 million through the cash exercise of 393,070 common stock purchase warrants. Each warrant was exercised to purchase one share of common stock for $4.75 per share. The warrants were originally issued as part of a financing completed in March 2014, and were exercised by several unaffiliated holders over the past six weeks. N
Oct 19, 2017 07:30 am ET
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy
BOTHELL, Wash., Oct. 19, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that its customer Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy. As announced in a July 2016 press r
Oct 18, 2017 07:30 am ET
BioLife Solutions to Present at Upcoming Investor Conferences
BOTHELL, Wash., Oct. 18, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that CEO Mike Rice and CFO Roderick de Greef will be attending and presenting at the following investor conferences:
Sep 19, 2017 07:30 am ET
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™
BOTHELL, Wash., Sept. 19, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), announced that Cellular Biomedicine Group (NASDAQ: CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases ("CBMG"), has validated BioLife's proprietary CryoStor freeze media for use in CBMG's planned US Phase I clinical trial of AlloJoin, an
Sep 07, 2017 07:30 am ET
BioLife Solutions to Present at September Investment Conferences
BOTHELL, Wash., Sept. 7, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), announces that Mike Rice, President and CEO, will be presenting at two investment conferences in September:
Aug 10, 2017 05:05 pm ET
BioLife Solutions Announces Second Quarter 2017 Financial Results
BOTHELL, Wash., Aug. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today reported operational highlights and financial results for the three and six months ended June 30, 2017.
Aug 03, 2017 07:30 am ET
BioLife Solutions to Report Second Quarter 2017 Financial Results and Provide Business Update on August 10, 2017
BOTHELL, Wash., Aug. 3, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's second quarter 2017 financial results will be released after market close on Thursday, August 10, 2017, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Jul 31, 2017 07:30 am ET
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers
BOTHELL, Wash., July 31, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that it has executed a long term supply agreement with NASDAQ-listed Celyad, a leader in the discovery and development of CAR-T cell therapies. BioLife's CryoStor clinical grade cell freeze media is incorporated into Celyad's manufacturing process for its Natural Killer Receptor based T-Cell (NKR-T) platform.
Jul 13, 2017 05:05 pm ET
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis
BOTHELL, Wash., July 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that Kolon Life Science, TissueGene's exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj., the world's first cell and gene therapy for degenerative arthritis from the Korea Ministry of Food and Drug Safety (MFDS).
Jul 05, 2017 07:00 am ET
BioLife Solutions Modifies Existing Credit Facility
BOTHELL, Wash., July 5, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that it has reached an agreement with WAVI Holding AG, ("WAVI") its debt holder and largest shareholder, to modify its existing credit facility effective June 30, 2017.
Jun 14, 2017 07:00 am ET
BioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform
BOTHELL, Wash., June 14, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has entered into a supply agreement with NASDAQ-listed Adaptimmune Therapeutics plc.
May 11, 2017 05:05 pm ET
BioLife Solutions Announces Q1 2017 Financial Results
BOTHELL, Wash., May 11, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today reported operational highlights and financial results for the first quarter of 2017.
May 04, 2017 07:30 am ET
BioLife Solutions to Report First Quarter 2017 Financial Results and Provide Business Update on May 11, 2017
BOTHELL, Wash., May 4, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's first quarter 2017 financial results will be released after market close on Thursday, May 11, 2017, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Mar 09, 2017 04:05 pm ET
BioLife Solutions Reports 4th Quarter and Full Year 2016 Results
BOTHELL, Wash., March 9, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today reported operational highlights and financial results for the fourth quarter and full year of 2016.
Mar 02, 2017 04:30 pm ET
BioLife Solutions to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update on March 9, 2017
BOTHELL, Wash., March 2, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's fourth quarter and full year 2016 financial results will be released on Thursday, March 9, 2017, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Feb 14, 2017 05:00 am ET
SAVSU Technologies Provides Performance Update on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics Phase 3 Glioblastoma Cell Therapy Clinical Trial
ALBUQUERQUE, N.M., Feb. 14, 2017 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart precision shipping containers and cloud based cold chain management SaaS solutions, today announced that its evo® Cold Chain 2.0™ live cell visibility platform has been successfully deployed in ImmunoCellular Therapeutics' phase 3 clinical trial of ICT-107, a patient-specific, dendritic cell-based immunotherapy for newly diagnosed glioblastoma. The ICT-107 trial (NCT02546102) will enroll up to 120 clinical sites in the US, Canada and Europe.
Jan 12, 2017 06:00 am ET
BioLife Solutions Announces 2016 Revenue Growth of 28%
BOTHELL, Wash., Jan. 12, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced preliminary 2016 revenue of $8.2 million, representing 28% growth in sales of biopreservation media products compared to the prior year.
Jan 10, 2017 06:00 am ET
BioLife Solutions Amends Existing Credit Facility
BOTHELL, Wash., Jan. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that it has reached an agreement to extend the maturity date and repayment schedule of its outstanding $4 million credit facility.
Jan 03, 2017 04:17 pm ET
BioLife Solutions Restructures biologistex™ Joint Venture
BOTHELL, Wash., Jan. 3, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife") today announced the restructuring of its biologistex CCM LLC joint venture (JV) formed with SAVSU Technologies LLC ("SAVSU"), to develop and commercialize the evo Smart Shipper and related biologistex Cold Chain Management SaaS.
Dec 20, 2016 06:00 am ET
BioLife Solutions Executes 10 Year Supply Agreement with TissueGene for CryoStor® Use in Invossa™ Osteoarthritis Cell-Mediated Gene Therapy
BOTHELL, Wash., Dec. 20, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has entered into a ten year supply agreement with TissueGene, a leading developer of regenerative therapies for the treatment of various orthopedic diseases.
Nov 10, 2016 04:05 pm ET
BioLife Solutions Reports Record Results for Third Quarter 2016
BOTHELL, Wash., Nov. 10, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today reported operational highlights and financial results for the three and nine months ended September 30, 2016.
Nov 03, 2016 07:00 am ET
BioLife Solutions to Report Third Quarter 2016 Financial Results and Provide Business Update on November 10, 2016
BOTHELL, Wash., Nov. 3, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that the Company's third quarter 2016 financial results will be released on Thursday, November 10, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results
Oct 26, 2016 07:00 am ET
BioLife Solutions and Brooks Life Sciences Partner on Study of Best Practices for Shipping and Storing Time and Temperature Sensitive Biologic Materials
BOTHELL, Wash., Oct. 26, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, and Brooks Automation, a leading worldwide provider of automation and cryogenic equipment for life sciences, recently collaborated on a shipping and storage study to support best distribution practices for time and temperature sensitive biologic materials. Both companies serve
Sep 15, 2016 07:00 am ET
BioLife Solutions' CryoStor® Embedded in Manufacturing Process for Promethera Biosciences HepaStem Cell-Based Treatment for Liver Disorders
BOTHELL, Wash., Sept. 15, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that its clinical grade CryoStor freeze media has been embedded into the manufacturing process for HepaStem, a cell-based treatment developed by Promethera Biosciences, targeting several metabolic liver disorders such as hemophilia a
Aug 24, 2016 07:00 am ET
BioLife Solutions' CryoStor® Integrated in Kolon Group's Cell-Mediated Gene Therapy for Osteoarthritis
BOTHELL, Wash., Aug. 24, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science.
Aug 11, 2016 05:05 pm ET
BioLife Solutions Reports Results for Second Quarter 2016
BOTHELL, Wash., Aug. 11, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today reported operational highlights and financial results for the three and six months ended June 30, 2016.
Aug 10, 2016 07:00 am ET
BioLife Solutions Executes 10 Year Supply Agreement with Bellicum Pharmaceuticals for CryoStor® Use in Cellular Immunotherapies
BOTHELL, Wash., Aug. 10, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has entered into a ten year supply agreement with Bellicum Pharmaceuticals, a leading developer of cellular immunotherapies for cancers and orphan inherited blood disorders.
Aug 03, 2016 07:00 pm ET
BioLife Solutions to Report Second Quarter 2016 Financial Results and Provide Business Update on August 11, 2016
BOTHELL, Wash., Aug. 3, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 11, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results a
Jul 18, 2016 07:00 am ET
BioLife Solutions Products Embedded in Cook MyoSite® Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
BOTHELL, Wash., July 18, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that its media products are embedded into the autologous cell therapy being developed by Pittsburgh-based Cook MyoSite, a subsidiary of the Cook Group, for treatment of female stress urinary incontinence.
Jul 11, 2016 07:30 am ET
BioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor® Use in CAR T Cell Therapies
BOTHELL, Wash., July 11, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has entered into a ten year supply agreement with Kite Pharma, a leading developer of chimeric antigen receptor (CAR) and T cell receptor (TCR) products for various cancers.
May 19, 2016 07:00 am ET
BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma
BOTHELL, Wash. and IRVINE, Calif., May 19, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that through its biologistex joint venture, it will partner with MNX Global Logistics to support the registrational phase 3 clinical trial being conducted by ImmunoCellular Therapeutics (NYSE MKT: IMUC) for their ICT
May 18, 2016 03:00 pm ET
BioLife Solutions Appoints Jim Mathers as New Vice President of Sales
BOTHELL, Wash., May 18, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has appointed Jim Mathers to the position of Vice President of Sales, replacing Matt Snyder, who is retiring.
May 12, 2016 05:05 pm ET
BioLife Solutions Reports First Quarter 2016 Results
BOTHELL, Wash., May 12, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today reported financial results and operational highlights for the first quarter of 2016 and that it had entered into $4 million credit facility with its largest shareholder.
May 06, 2016 07:30 am ET
BioLife Solutions to Report First Quarter 2016 Financial Results and Provide Business Update on May 12, 2016
BOTHELL, Wash., May 6, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that the Company's first quarter 2016 financial results will be released on Thursday, May 12, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a
May 04, 2016 07:00 am ET
BioLife Solutions Names Roderick de Greef Chief Financial Officer & Secretary
BOTHELL, Wash., May 4, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Roderick de Greef has transitioned from Interim Chief Financial Officer and Secretary to full time employment and is relocating to the Seattle area.
May 02, 2016 09:00 am ET
MNX Global Logistics and Biologistex, LLC Offer Proactive and Real-time Shipment Monitoring of Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
IRVINE, Calif., May 2, 2016 /PRNewswire/ -- MNX Global Logistics, a global leader providing expedited and cold-chain transportation and logistics solutions to the life sciences and biopharmaceutical industry, announced today that it is expanding its GPS and cellular location-based real-time shipment integrity monitoring services through a partnership with Biologistex, LLC, a joint venture of BioLife Solutions (NASDAQ:BLFS) and SAVSU Technologies, a subsidiary of privately held Barson Corporation.
May 02, 2016 07:30 am ET
Seattle Business Magazine Names BioLife Solutions Washington State Manufacturer of the Year
BOTHELL, Wash., May 2, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, announced that on May 1st, it was named Washington State Manufacturer of the Year, for the small firm category by Seattle Business Magazine.
Apr 26, 2016 07:00 am ET
Biologistex LLC and MNX Global Logistics Partner to Offer Enhanced Cold Chain Logistics Services for Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
BOTHELL, Wash. and IRVINE, Calif., April 26, 2016 /PRNewswire/ -- Biologistex CCM, LLC, a joint venture of BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, and SAVSU Technologies, LLC, a leading designer and manufacturer of innovative high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, today announced a partne
Apr 04, 2016 07:30 am ET
BioLife Solutions Names Cord Blood Industry Veteran Karen Foster Vice President of Operations
BOTHELL, Wash., April 4, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Karen Foster will join the Company as Vice President of Operations effective April 13, 2016. She was previously Vice President of Laboratory Operations and Site Leader at ViaCord, LLC, a family cord blood bank, and subsidiary of PerkinElmer Inc.
Mar 14, 2016 07:30 am ET
BioLife Solutions Provides Update on Customer Cell Therapy Clinical Trials and Development Programs
BOTHELL, Wash., March 14, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today provided an update on several customer clinical trials and development programs using cellular therapies and cellular immunotherapies in human regenerative medicine applications. Key developments include:
Mar 09, 2016 06:00 am ET
BioLife Solutions to Present at 28th Annual ROTH Conference and 4th Annual ARM Cell & Gene Therapy Investor Day
BOTHELL, Wash., March 9, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced CEO Mike Rice will be presenting at two upcoming investor events;
Mar 07, 2016 06:30 am ET
BioLife Solutions Names Roderick de Greef Interim Chief Financial Officer
BOTHELL, Wash., March 7, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Roderick de Greef has joined the Company as interim Chief Financial Officer and Secretary. He previously served on BioLife's board of directors for over a decade through 2013.
Feb 25, 2016 04:05 pm ET
BioLife Solutions Reports 4th Quarter and Full Year 2015 Results
BOTHELL, Wash., Feb. 25, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today reported financial results and operational highlights for the fourth quarter and full year 2015.
Feb 22, 2016 06:00 am ET
BioLife Solutions to Report Fourth Quarter 2015 Financial Results and Provide Business Update on February 25, 2016
BOTHELL, Wash., Feb. 22, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that the Company's fourth quarter 2015 financial results will be released on Thursday, February 25, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial resul
Jan 27, 2016 06:00 am ET
BioLife Solutions to Present at 18th Annual BIO CEO & Investors Conference
BOTHELL, Wash., Jan. 27, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, announced today that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference being held February 8-9, 2016 at the Waldorf Astoria in New York City. Mike Rice, Chief Executive Officer at BioLife Solutions, will be presenting at 5:00 PM ET on Monday,
Jan 25, 2016 06:00 am ET
New Journal Articles Cite Expanded Use of BioLife Solutions Products in Clinical Cell Therapy Applications
BOTHELL, Wash., Jan. 25, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers today announced that two recently published journal articles cite expanded use of the Company's CryoStor cell freeze media in pre-clinical safety studies and clinical trials of cellular therapies for liver transplantation and heart failure.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.